In a study conducted by Jillian A. et al. [222], a liquid biopsy approach was used to assess PD-L1 expression on tumor-associated cells to track lung cancer recurrence and metastasis in patients undergoing treatment with immune checkpoint inhibitors. The gene discussed is CD274; the disease is lung carcinoma.